{"id":"adjuvanted-pandemic-influenza-candidate-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or erythema"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Fever"}]},"_chembl":{"chemblId":"CHEMBL2109042","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine contains inactivated or recombinant influenza virus antigens combined with an adjuvant (likely AS04, containing aluminum hydroxide and MPL) that amplifies the body's innate and adaptive immune responses. This adjuvanted formulation is designed to provide enhanced immunogenicity and potentially broader or more durable protection against pandemic influenza strains compared to non-adjuvanted vaccines.","oneSentence":"This vaccine stimulates the immune system to recognize and respond to pandemic influenza virus antigens, with an adjuvant component to enhance the immune response.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:52.237Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pandemic influenza prevention in adults"}]},"trialDetails":[{"nctId":"NCT00449670","phase":"PHASE3","title":"Assess Consistency of Immunogenicity of GlaxoSmithKline Biologicals' Pandemic Influenza Vaccine (GSK1562902A) in Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-03-24","conditions":"Influenza, Influenza Vaccines","enrollment":1206},{"nctId":"NCT00306995","phase":"PHASE2","title":"Safety Study of Pandemic Candidate Influenza Vaccines in the Elderly Population","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2005-05-11","conditions":"Influenza, Influenza Vaccines","enrollment":385},{"nctId":"NCT00397215","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Adults Over 60 Years of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-11-17","conditions":"Influenza","enrollment":437},{"nctId":"NCT00502593","phase":"PHASE2","title":"Evaluate Safety & Immunogenicity of a Pandemic Influenza Vaccine (GSK1562902A) in Children","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-07-23","conditions":"Influenza","enrollment":138},{"nctId":"NCT00742885","phase":"PHASE2","title":"Immunogenicity and Safety of GSK Biologicals' (Pre-) Pandemic Influenza Candidate Vaccine","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-09-01","conditions":"Influenza","enrollment":100},{"nctId":"NCT01035749","phase":"PHASE2","title":"Study of GSK Biologicals' Pandemic Influenza (H1N1) Candidate Vaccine in Children Aged 10 to Less Than 18 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-02-01","conditions":"Influenza","enrollment":310},{"nctId":"NCT00652743","phase":"PHASE3","title":"Immunogenicity of GSK Biologicals' Pandemic Influenza Vaccine (GSK1562902A) at Different Boosting Vaccination Schedules","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2008-03-23","conditions":"Influenza","enrollment":845},{"nctId":"NCT00319098","phase":"PHASE3","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged 18 Years and Above","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-05-01","conditions":"Influenza","enrollment":5075},{"nctId":"NCT00506350","phase":"PHASE2","title":"Evaluate Reactogenicity & Immunogenicity of an Influenza Pandemic Candidate Vaccine (GSK1562902A) in Primed Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-08-01","conditions":"Influenza","enrollment":350},{"nctId":"NCT00309634","phase":"PHASE1","title":"Study to Evaluate the Safety and Immunogenicity of a Pandemic Influenza Vaccine in Adults Aged Between 18 and 60 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2006-03-27","conditions":"Influenza","enrollment":400},{"nctId":"NCT00841646","phase":"PHASE2","title":"Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-12","conditions":"Prepandemic Influenza Vaccine","enrollment":343},{"nctId":"NCT00848029","phase":"PHASE3","title":"Safety and Immunogenicity of Two Doses of Monovalent Inactivated Influenza Vaccine That is Adjuvanted With MF59C.1 (MF59) and Uses a Surface Antigen From a Potential Pandemic Virus Strain Candidate (H5N1) in Adult and Elderly Subjects Using Four Different Vaccination Schedules","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2008-11","conditions":"Pre-pandemic Influenza Vaccine","enrollment":240},{"nctId":"NCT01111968","phase":"PHASE1","title":"Evaluation of Pandemic Influenza A (H1N1)Candidate Vaccines","status":"COMPLETED","sponsor":"Butantan Institute","startDate":"2010-01","conditions":"Influenza","enrollment":266}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Adjuvanted pandemic influenza candidate vaccine","genericName":"Adjuvanted pandemic influenza candidate vaccine","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to recognize and respond to pandemic influenza virus antigens, with an adjuvant component to enhance the immune response. Used for Pandemic influenza prevention in adults.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}